Similar articles

• Interpreting and evaluating the details of the JUPITER study.

  Neft M. Neft M. Am Fam Physician. 2010 Sep 15;82(6):571-7; author reply 571-7. Am Fam Physician. 2010. PMID: 20842982 No abstract available.
• Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

  Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Ridker PM, et al. Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22. Circ Cardiovasc Qual Outcomes. 2009. PMID: 20031900 Clinical Trial.
• Rosuvastatin for cardiovascular prevention: too many uncertainties.

  [No authors listed] [No authors listed] Prescrire Int. 2009 Aug;18(102):176. Prescrire Int. 2009. PMID: 19746571
• The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.

  Kones R. Kones R. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):309-15. doi: 10.1177/1753944709337056. Epub 2009 May 21. Ther Adv Cardiovasc Dis. 2009. PMID: 19460829 Review.
• Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.

  de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, Okuyama H, Pavy B, Rabaeus M. de Lorgeril M, et al. Arch Intern Med. 2010 Jun 28;170(12):1032-6. doi: 10.1001/archinternmed.2010.184. Arch Intern Med. 2010. PMID: 20585068 Review.